FeesSafety
Pluang+

FingerMotion eyes $100M revenue from 7 MW AI/HPC colocation deal at Brooks Campus #1 in Alberta

Market News
04 Nov 2026, 18:00 WIB
GlobeNewsWire
View Source
Bullish
FingerMotion eyes $100M revenue from 7 MW AI/HPC colocation deal at Brooks Campus #1 in Alberta

FingerMotion's subsidiary Brooks Campus No. 1 Inc. signed a non-binding letter of interest with Cascadia Power for up to 7 MW of liquid-cooled AI/HPC colocation capacity at Brooks Campus #1 in Alberta. The deal could generate over $100 million in revenue over five years if finalized, with the first tranche ready in six months and full capacity in 12-14 months. This project supports FingerMotion's broader 99 MW Alberta power and compute program, aiming to meet strong demand for reliable, behind-the-meter AI/HPC infrastructure. Negotiations continue under a 30-day exclusivity period to finalize binding agreements.

FingerMotion's AI/HPC colocation deal is the subject, with Pluang market data as context for readers. As of Nov 04, 2026 22:42 WIB, 88 of 150 Technology-sector US stocks on Pluang rose while 62 fell. Notable movers include DDOG at USD 193.50 with a -12.25% change and 0% Sell / 100% Buy order activity, LYFT up 11.79% at USD 18.64, and CORZ down 9.87% at USD 12.84 with 0% Sell / 100% Buy orders. The most notable figure is LYFT's 11.79% gain.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
19 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
19 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
19 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
19 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
19 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App